朱传娴

客户顾问

hzhu@acs-i.org

SciFinder文献检索难点解析

2017.12

SCIFINDER®
A CAS SOLUTION

提纲

- SciFinder文献检索难点解析
  - 如何获得更全面的结果集
  - 利用Index Term修正检索词
  - 巧用CAS Role
  - 善用Categorize
  - 避免标引时差引起的漏检

SciFinder检索——文献检索

- 文献检索方法
  - 主题检索
  - 作者名检索
  - 机构名检索
  - 文献标识符检索
  - 期刊名称和专利信息（公开号，申请号等）
  - 从物质，反应获得文献

- 检索策略推荐
  - 关注某特定领域的文献：主题检索
  - 关注物质有关的文献：先获得物质，再获得文献
  - 关注某科研人员的文献：作者名检索
  - 关注某机构科研进展：机构名检索

SCIFINDER® A CAS SOLUTION

浏览结果集发现关键词

主题检索：阿奇霉素的结构修饰

检索式： Modification of Azithromycin

关键词之间用介词连接：in, with, of...

SciFinder
A CAS SOLUTION

浏览结果集发现关键词

"Concepts"表示对主题词做了同义词的扩展；

"Closely associated with one another"表示同时出现在一个句子中;

"were present anywhere in the reference"表示同时出现在一篇文献中；

SciFinder
A CAS SOLUTION

浏览结果集发现关键词

Save：保存结果集于服务器上，方便随时查看



获得检索结果集之后首先要随机浏览记录，判断是否是相关文献、
是否符合检索要求、是否有更好的关键词，如有必要需要调整检索式

浏览结果集发现关键词

10. Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect

By: Gardarsson, Friorik; Guldberg, Susanne; Gardarsson, Magnus
Assignee: Iceland

The invention provides mols., which are based on a modification of azithromycin, removing the antibiotic effect, while retaining other beneficial effects, such as, but not limited to immunomodulatory effects. The compds. of the invention can be described by compds. of Formula (I) as further defined herein.

Patent Information

Patent No.	Kind	Language	Date	Application No.	Date
US 20160031925 PATENTPAK	A1		Feb 4, 2016	US 2015-14783245	Oct 8, 2015
WO 2014166503 PATENTPAK	A1	English	Oct 16, 2014	WO 2014-DK50092	Apr 10, 2014

Priority Application

IS 2013-50050	A	Apr 10, 2013
WO 2014-DK50092	W	Apr 10, 2014

Indexing

Carbohydrates (Section33-7)

Section cross-reference(s): 1, 10, 63

Concepts

Bronchiolitis

diffuse panbronchiolitis; prepn. of azithromycin antimicrobial derivs. with non-antibiotic pharmaceutical effect

Adult respiratory distress syndrome
Antibacterial agents
Antimicrobial agents
Bacterial infection
Chronic bronchitis
Crohn disease
Immune disease
Inflammation
Intestine
Rheumatoid arthritis
Antiasthmatics
Antibiotics
Asthma
Bronchitis
Chronic obstructive pulmonary disease
Cystic fibrosis
Immunomodulators
Inflammatory bowel disease
Macrolide antibiotics

Substances

1092100-82-7P

prepn. of azithromycin antimicrobial derivs. with non-antibiotic pharmaceutical effect

Catalyst use; Synthetic preparation; Preparation; Uses

586967-35-3P
1349581-16-3P
1631161-49-3P
1631161-50-6P
1631161-51-7P
1631161-52-8P
1631161-53-9P
1631161-54-0P

prepn. of azithromycin antimicrobial derivs. with non-antibiotic pharmaceutical effect

获得重要相关词，可再次检索

SciFinder® A CAS SOLUTION

浏览结果集发现关键词


CAS Solutions
SciFinder
A CAS SOLUTION
Explore
Saved Searches
SciPlanner
Research Topic "derivatives of azithromycin "
REFERENCES
Research Topic
Author Name
Company Name
Document Identifier
Journal
Patent
Tags
SUBSTANCES
Chemical Structure
Markush
REFERENCES: RESEARCH TOPIC
derivative of azithromycin
Examples:
Preferences | SciFinder Help
Sign Out
Welcome Helen Zhu
Save
Print
Export
58 duplicates were automatically removed.
Research Topic "derivative of azithromycin " > references (312)
Get Substances
Get Reactions
Get Related Citations
Tools
Select to view available menu items.
Create Keep Me Posted Alert
Send to SciPlanner
Remove Duplicates
Combine Answer Sets
Add Tag
Analyze
Refine
Categorize
Sort by: Accession Number
Display Options
0 of 312 References Selected
Page: 1 of 16
Analyze by:
Author Name
Ma Shutao 18
Alihodzic Sulejman 13
Lazarevski Gorjana 11
Shen Shunyi 11
Ge Han 10
Kobrehel Gabrijela 7
Mutak Stjepan 7
Cong Chao 6
Li Xin 6
Cui Wenping 5
Show More
1. Toward the rational design of macrolide antibiotics to combat resistance
2. Fructose injection of antibiotic medicine
3. Around the macrolide - Impact of 3D structure
Combine Answer Sets
Select saved answer set(s) to combine with your current answer set (312):
56 Answer Sets 1 Selected
Reference Answer Set Details
Date Saved
Azm sub (97)
Jul 14, 2017
Azi Substructure (30)
Jul 13, 2017
modification of Azithromycin (137)
Jul 13, 2017
Jun 5, 2017
Select an option for combining the answer sets:
Combine
Include all answers from both sets
Intersect
Include only answers that appear in both sets
Exclude
Include only answers from current answer set (312) that are not in modification of Azithromycin (137)
Exclude
Include only answers from modification of Azithromycin (137) that are not in current answer set (312)
Combine Answer Sets
Cancel

浏览结果集发现关键词

获得全面的结果集是做好文献调研的首要条件
SciFinder提供强大的文献处理工具，帮助处理文献

利用Inder Term选词

主题检索：植物中天然活性成分的抗癌研究

检索式： Natural Active Component with Anti Cancer

关键词之间用介词连接：in, with, of...

SciFinder
A CAS SOLUTION

主题检索的候选项



"Concepts"表示对主题词做了同义词的扩展；

"Closely associated with one another"表示同时出现在一个句子中;

"were present anywhere in the reference"表示同时出现在一篇文献中；

SciFinder
A CAS SOLUTION

利用Index Term选词



利用Index Term选词





Index Term基于内容的分析工具，发现natural products, Pharmaceutical 这个和天然活性成分很相关的词

是否用这个词去检索，效果会更好？

SciFinder® A CAS SOLUTION

利用Index Term选词





新的检索式：

Natural Product with anti cancer

更换检索词后，结果放大近70倍

SciFinder® A CAS SOLUTION

STN中的CAS Role

ANST Analytical Study

Analyte	ANT
Analytical Matrix	AMX
Analytical Reagent Use	ARG
Analytical Role, Unclassified	ARU

PREP Preparation

Bioindustrial Manufacture	BMF
Biosynthetic Preparation	BPN
Byproduct	BYP
Industrial Manufacture	IMF
Preparation, Unclassified	PNU
Purification or Recovery	PUR
Synthetic Preparation	SPN

PROC Process

Biochemical Process	BCP
Biological Process	BPR
Geological or Astronomical Process	GPR
Physical, Engineering, or Chemical Process	PEP
Removal or Disposal	REM

BIOL Biological Study

Adverse Effect, Including Toxicity	ADV
Agricultural Use	AGR
Biological Activity or Effector, Except Adverse	BAC
Biochemical Process	BCP
Bioindustrial Manufacture	BMF
Biological Occurrence	BOC
Biosynthetic Preparation	BPN
Biological Process	BPR
Biological Study, Unclassified	BSU
Biological Use, Unclassified	BUU
Cosmetic Use	COS
Diagnostic Use	DGN
Food or Feed Use	FFD
Natural Product Occurrence	NPO
Pharmacological Activity	PAC
Pharmacokinetics	PKT
Therapeutic Use	THU

STN中的CAS Role

FORM	**Formation, Nonpreparative**	
	Formation, Unclassified	FMU
	Geological or Astronomical Formation	GFM
NANO	**Nanomaterial**	
OCCU	**Occurrence**	
	Biological Occurrence	BOC
	Geological or Astronomical Occurrence	GOC
	Natural Product Occurrence	NPO
	Occurrence, Unclassified	OCU
	Pollutant	POL

RACT	**Reactant or Reagent**	
	Reactant	RCT
	Reagent	RGT
USES	**Uses**	
	Agricultural Use	AGR
	Analytical Reagent Use	ARG
	Biological Use, Unclassified	BUU
	Catalyst Use	CAT
	Cosmetic Use	COS
	Diagnostic Use	DGN
	Food or Feed Use	FFD
	Modifier or Additive Use	MOA
	Other Use, Unclassified	NUU
	Polymer in Formulation	POF
	Technical or Engineered Material Use	TEM
	Therapeutic Use	THU

SciFinder® A CAS SOLUTION

巧用CAS Role

查找纯化双氧水（7722-84-1）的文献



SCIFINDER® A CAS SOLUTION

巧用CAS Role

1. A method for a kind of tailwater cascade oxidation depth purification [Machine Translation].

By: Liu, Fuqiang; Luo, Kun; Shuang, Chendong; Hu, Dabo; Zhao, Wei; Jiang, Bicun; Yan, Tingting; Li, Jianhua; Li, Aimin
Assignee: Nanjing University, Peop. Rep. China

[Machine Translation of Descriptors]. The invention discloses a kind of biochem. oxidn. cascade tail water depth purifn. method, belongs to biochem. tail water depth treatment tech. field. The present invention firstly adopts ferrous and hydrogen peroxide to carry out oxidn. to participate in the pre-oxidn., then using subsequent preliminary sedimentation stage when pH is 2.5~ 6 formed on iron mud waste water adsorption and flocculation, remove part of org. and inorg. phosphorus, Reduce photocatalytic oxidn. strengthen weakened section of org. and inorg. phosphorus load impact; further use of catalytic oxidn. depth to remove orgs., strengthen the subsequent secondary sedimentation stage pH as 6-9, the formation of iron mud back to pre-oxidn. section, as a catalyst recycling, reduce medicine consumption and low sludge amt. The present invention also play the pre-oxidn. zone hydroxyl free radical reaction is quick and has broad-spectrum resistance characteristics, and effectively utilizes neutralization pptn. when different pH scope formed iron mud adsorption characteristics and catalytic activity, significantly improves the reaction efficiency, low reagent consumption, and effectively realize the recycling of iron mud.

Patent Information

Patent No.	Kind	Language	Date	Application No.	Date
CN 106007080	A		Oct 12, 2016	CN 2016-10521105	Jul 1, 2016

Priority Application

CN 2016-10521105	Jul 1, 2016

Indexing

Waste Treatment and Disposal (Section60)

Concepts

Adsorption
Sludges
Recycling
pH

a method for a kind of tailwater cascade oxidn. depth purifn. [Machine Translation].

Substances

1333-74-0 Hydrogen
7439-89-6 Iron
7722-84-1 Hydrogen peroxide (H2O2)

7723-14-0 Phosphorus

a method for a kind of tailwater cascade oxidn. depth purifn. [Machine Translation].

Pollutant; Removal or disposal; Occurrence; Process

噪音信息

SciFinder® A CAS SOLUTION

巧用CAS Role


CAS Solutions
SciFinder
A CAS SOLUTION
Preferences | SciFinder Help
Sign Out
Welcome Helen Zhu
Explore
Saved Searches
SciPlanner
Save
Print
Export
Research Topic "purify of 7722-84-1" > references (2126) > Method for preparing light wei...
REFERENCES
Get Substances
Get Reactions
Get Related
Create Keep Me Posted Alert
Send to SciPlanner
Analyze
Refine
Categorize
Sort by: Accession Number
Display Options
0 of 2126 References Selected
Page: 2 of 107
Analyze by:
Author Name
Jiang Wenlan 30
Xu Qinghua 30
Xu Shengying 30
Yuan Changbing 30
Yuan Xin 28
Kagawa Kenkichi 23
Odo Tsunahiro 18
Saito Tomomi 18
Tanaka Toshio 18
Mabuchi Kimihiro 12
21. Zinc oxide concentrate purification
Quick View
PATENTPAK
By Yu, Qiongpeng
From Faming Zhuanli Shenqing (2016), CN 105
The present invention discloses a zin
evapn. and concn., the prepn. of pre
condition, high product uniformity, lov
iron removal by oxidn., demanganization, heavy metal removal,
rior art, the present invention has simple process, mild reaction
22. Systematic comparison of conventi
Quick View
Other Sources
By Clancy, Adam J.; White, Edward R.; Tay, Hu
From Carbon (2016), 108, 423-432. | Languag
As-synthesized single-walled carbon
effect on the effective mech. and ele
gas phase purifications and recenti
selected for its potential scalability to
sidual catalyst particles. These contaminants have a detrimental
rative series of SWCNT purifications including acid treatments,
om. SWCNT type (Tuball). Each of the purifn. procedures was
23. Method for preparing light weight high-efficient supported photocatalyst for air purifier
Quick View
PATENTPAK
By Yang, Lixin
From Faming Zhuanli Shenqing (2016), CN 105797705 A 20160727. | Language: Chinese, Database: CAPLUS
The title method comprises immersing photocatalyst hydrosol by a light wt. carrier, and prepg. light wt. high-efficient supported photocatalyst for air purifier. The prepn. method
Save This Answer Set
* Required
Save:
All answers
Only selected answers
Title: *
purify of H2O2
Description:
OK
Cancel

巧用CAS Role



SciFinder® A CAS SOLUTION

巧用CAS Role


CAS Solutions
SciFinder
A CAS SOLUTION
Preferences | SciFinder Help
Sign Out
Welcome Helen Zhu
Explore
Saved Searches
SciPlanner
Save
Print
Export
Duplicates not removed. Answer set exceeds 10,000 reference limit.
Substance Identifier "7722-84-1 " > substances (1) > get references (14672)
REFERENCES
Get Substances
Get Reactions
Get Related Citations
Tools
Create Keep Me Posted Alert
Send to SciPlanner
Analyze
Refine
Categorize
Sort by: Accession Number
Remove Duplicates
Combine Answer Sets
Add Tag
Display Options
0 of 14672 References Selected
Page: 1 of 734
Analyze by:
Author Name
Hutchings Graham J 49
Wang Erzhong 45
Wang Li 40
Edwards Jennifer K 39
Carley Albert F 36
Kornienko V L 31
Yamanaka Ichiro 31
Mi Zhentao 30
Kiely Christopher J 28
Brillas Enric 27
1. Hydrogen peroxide working solution continuous preparation apparatus [Machine Translation].
Quick View
Combine Answer Sets
Select saved answer set(s) to combine with your current answer set (14672):
43 Answer Sets 1 Selected
Reference Answer Set Details
Date Saved
purify of H2O2 (2126)
Research Topic "purify of 7722-84-1" > references (2126)
Oct 19, 2016
remove 6 (6)
Research Topic "remove of 123-39-7" > references (49) > refine by categories
Oct 19, 2016
purify of 7722-84-1 (2124)
Research Topic "purify of 7722-84-1" > references (2124)
Oct 17, 2016
remove 123-39-7 (9) (9)
Substance Identifier "123-39-7 " > substances (1) > get references (384) > Combine Reference Answer Sets "remove DMF 49 (49)" (9)
Oct 17, 2016
Select an option for combining the answer sets:
Combine
Include all answers from both sets
Intersect
Include only answers that appear in both sets
Exclude
Include only answers from current answer set (14672) that are not in purify of H2O2 (2126)
Exclude
Include only answers from purify of H2O2 (2126) that are not in current answer set (14672)
Combine Answer Sets
Cancel
2. Immobilization of
Quick View
A CAS SOLUTION

巧用CAS Role



浏览记录，判断是否符合要求

SciFinder
A CAS SOLUTION

巧用CAS Role

1. Hydrogen peroxide purification adsorbent preparation method

By: Wang, Qiyu
Assignee: Wang, Jinming, Peop. Rep. China

The invention relates to a hydrogen peroxide purifn. adsorbent prepn. method. The method comprises: using o-fluorobenzoyl group modification to obtain composite functional resin, introducing strong-withdrawing electron group 4-fluorobenzoyl Me to form antioxidant group to improve the life of the resin in the hydrogen peroxide oxidn. conditions, and introducing fluorine-contg. group to enhance corrosion resistance of the resin skeleton. The sphere surface is protected, thus extending the life.

Patent Information

Patent No.	Kind	Language	Date	Application No.	Date
CN 105749877 PATENTPAK	A		Jul 13, 2016		

Priority Application

CN 2015-10852280	Nov 26, 2015

7722-84-1P Hydrogen peroxide, preparation Page 2 in PATENTPAK

hydrogen peroxide purifn. adsorbent prepn. method

Purification or recovery; Preparation

8. Method of purifying hydrogen peroxide using reverse osmosis membrane and ion exchangers

By: Myung, Jung Jae
Assignee: Dongwoo Fine-Chem Co., Ltd., S. Korea

The invention relates to a method of purifying H_2O_2 by using a reverse osmosis membrane which is a C nanomaterial-coated porous polymer scaffolds, an anion exchange resin and a cation exchange resin. More specifically, the invention relates to a method of purifying H_2O_2 characterized by passing H_2O_2 through a cation exchange resin and an anion exchange resin after passing through a reverse osmosis membrane coated with C nanomaterials over porous polymer scaffolds.

7722-84-1P Hydrogen peroxide (H2O2), preparation Page 2 in PATENTPAK

method of purifying hydrogen peroxide using reverse osmosis membrane and ion exchangers

Purification or recovery; Preparation

都是需要的文献

SCIFINDER® A CAS SOLUTION

善用Categorize

检索文献：

1. 去除N-甲基甲酰胺（123-39-7）的文献？
2. 用N-甲基甲酰胺（123-39-7）作洗脱剂的文献？

SciFinder® A CAS SOLUTION

善用Categorize

去除N-甲基甲酰胺（123-39-7）



SciFinder®
A CAS SOLUTION

善用Categorize

1. Removal of gas phase dimethylamine and N,N-dimethylformamide using non-thermal plasma

By: Wang, Wenzheng; Fan, Xing; Zhu, Tianle; Wang, Haining; Ye, Daiqi; Hong, Xiaowei

Dimethylamine (DMA) and N,N-dimethylformamide (DMF) are typical N-VOCs exhausted from manufg. factories. In the present study, the behavior of non-thermal plasma (NTP) was systematically investigated for removal of gas-phase DMA and DMF in a link tooth wheel-cylinder plasma reactor. Exptl. results show that DMA is much easier to be decompd. by NTP than DMF. Coexisting DMF has no effect on DMA conversion while DMF conversion is significantly promoted by the addn. of DMA. Regardless of initial gas compns. as well as DMA and DMF concn., CO_x selectivity increased monotonously with increasing ED. But CO_x selectivity of 100% cannot be obtained even with ED higher than 70 J L^{-1}, indicating the formation of org. intermediates during DMA and DMF decompn. Based on org. products anal. with GC-MS and mol. optimization results with d. functional theory calcn., possible mechanisms on DMA and DMF degrdn. were proposed. The org. products from DMA and DMF decompn. by NTP were found to have great soly. and high biodegradability. Thus, NTP enhanced absorption/biol. method is suggested for complete removal of DMA and DMF.

Indexing

Air Pollution and Industrial Hygiene (Section59-4)

Concepts

Absorption
Air pollution control
Bond energy
Bond length
Decomposition
Decomposition catalysts
Plasma
Waste gas treatment

removal of gas phase dimethylamine and N,N-dimethylformamide using non-thermal plasma

Volatile organic compounds

removal of gas phase dimethylamine and N,N-dimethylformamide using non-thermal plasma

Removal or disposal; Process

Substances

56-40-6 Glycine, formation (nonpreparative)
64-18-6 Formic acid, formation (nonpreparative)
75-12-7 Formamide, formation (nonpreparative)
79-20-9 Methyl acetate
105-37-3 Ethyl propionate
107-31-3 Methyl formate
123-39-7 N-Methyl formamide



144-62-7 Oxalic acid, formation (nonpreparative)

removal of gas phase dimethylamine and N,N-dimethylformamide using non-thermal plasma

Formation, unclassified; Formation, nonpreparative

需要的文献

SciFinder® A CAS SOLUTION

善用Categorize

3. Removing agent containing alkylamide mixture

By: Li, Bo; Yu, Ran
Assignee: Qingdao Hui Cheng Petrochemical Technology Co., Ltd., Peop. Rep. China

The present invention relates to a kind of alkylamide removing agent. The removing agent comprises N-methylformamide 50-70 wt.%, N, N-dimethyl acetamide 30-50 wt.% and water as balance. The alkylamide removing agent of the present invention has water compatibility, and has no corrosivity for copper or copper alloy, and is generally nontoxic to mankind and environment. Because the constituent of alkylamide removing agent only comprises two main constituents, the removing agent after use can be easily by fractionation and recombine to original formula, and can be recycled to apply in the prepn. process to achieve the effect of reducing cost and environmental protection. The present invention also provides a method of using the removing agent of the present invention to remove photoresist.

Patent Information

Patent No.	Kind	Language	Date	Application No.	Date
CN 104698775 PATENTPAK	A		Jun 10, 2015	CN 2013-10646205	Dec 4, 2013

Priority Application

CN 2013-10646205	Dec 4, 2013

Indexing

Radiation Chemistry, Photochemistry, and Photographic and Other Reprographic Processes (Section74-5)

Concepts

Coating removers — Photoresists

removing agent contg. alkylamide mixt.

Amides

removing agent contg. alkylamide mixt.

Other use, unclassified; Physical, engineering or chemical process; Process; Uses

Substances

123-39-7 N-Methylformamide



127-19-5 N, N-Dimethyl acetamide

removing agent contg. alkylamide mixt.

Other use, unclassified; Physical, engineering or chemical process; Process; Uses

噪音信息更多，如何去除？

SciFinder® A CAS SOLUTION

善用Categorize



SciFinder
A CAS SOLUTION

善用Categorize



SciFinder®
A CAS SOLUTION

避免标引时差引起的漏检

Update frequency

- Updated daily
- Patent references from nine major issuing authorities available within two days from the time the patent was issued

9大核心专利机构发布的专利2日内收录进SciFinder

Bibliographic information and abstracts for all articles in more than 1,500 key scientific journals are added to CAplus[SM] within 7 days. The list below is sorted alphabetically by the full journal title and also includes the journal abbreviation and CODEN. This is not the full list of publications covered by CAS, and the list is subject to change.

核心期刊的文献7日内收录进SciFinder

对核心期刊及核心专利机构发布的专利的标引在2-3周内完成

在收录至标引期间的文献可能会漏检！

SciFinder® A CAS SOLUTION

避免标引时差引起的漏检

检索治疗肝病的药物Daclatasvir的相关文献



通过检索物质获得文献准确，但是不够新

SCIFINDER® A CAS SOLUTION

避免标引时差引起的漏检



通过主题直接检索物质名称，发现最新的文献

SCIFINDER® A CAS SOLUTION

避免标引时差引起的漏检



通过PY限定最新的文献，与通过物质检索获得的结果集合并

SciFinder® A CAS SOLUTION

避免标引时差引起的漏检

1. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis

By: Toyoda, Hindeori; Kumada, Takashi; Tada, Toshifumi; Takaguchi, Koichi; Ishikawa, Toru; Tsuji, Kunihiko; Zeniya, Mikio; Iio, Etsuko; Tanaka, Yasuhito

Background: Hepatitis C virus (HCV) infection is a major comorbidity in patients receiving hemodialysis. Interferon-based antiviral therapy to eradicate HCV is less effective in patients receiving hemodialysis than patients without renal dysfunction. Recently reported combination therapy with two oral direct-acting antiviral drugs, daclatasvir and asunaprevir, both of which are metabolized in the liver and excreted into the bile ducts, reportedly showed a high rate of HCV eradication. We evaluated the safety and efficacy of this therapy in patients receiving hemodialysis. Methods: The safety and viral responses were compared among patients infected with HCV genotype 1, between 28 patients receiving hemodialysis, and propensity score-matched 56 patients without renal dysfunction. Results: The redn. in serum HCV RNA levels 1 day after the start of therapy was significantly larger ($p = 0.0329$) and the disappearance of serum HCV RNA occurred significantly earlier ($p = 0.0017$) in patients receiving hemodialysis than those without renal dysfunction. The rates of sustained virol. response, i.e., the eradication of HCV, were comparable between two groups; the rate of SVR12 was 100 % in patients receiving hemodialysis and 94.6 % in patients without renal dysfunction. No adverse constitutional events were obsd. in either of the groups. The elevation of serum alanine aminotransferase levels, a known adverse effect of these drugs, was obsd. in comparable rate of patients between the two groups. Conclusions: The therapy with daclatasvir and asunaprevir has high antiviral efficacy in patients receiving hemodialysis with

Indexing

Pharmacology (Section1)

Citations

Anon; Tada T, Kumada T, Toyoda H, et al Viral eradication reduces all-cause mortality in pat
Berenguer, M; Hepatology, 10.1002/hep.22545 2008, 48, 1690
Chayama, K; Hepatology, 10.1002/hep.24724 2012, 55, 724
Deltenre, P; Alim Pharmacol Ther, 10.1111/j.1365-2036.2011.04741.x 2011, 34, 454
Espinosa, M; Nephrol Dial Transplant, 10.1093/ndt/16.8.1669 2001, 16, 1669

标引未完成

17. The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay

By: Kan, Toshiki; Hashimoto, Senju; Kawabe, Naoto; Murao, Michihito; Nakano, Takuji; Shimazaki, Hiroaki; Nakaoka, Kazunori; Ohki, Masashi; Takagawa, Yuka; Kurashita, Takamitsu; Takamura, Tomoki; Yoshioka, Kentaro

Background: Resistance-assocd. variants (RAVs) reduce the efficacy of interferon (IFN)-free therapy with asunaprevir and daclatasvir for patients infected with hepatitis C virus (HCV) genotype 1b. The characteristics of patients with an L31 or a Y93 variant in the nonstructural 5A region detected by a polymerase chain reaction invader assay were investigated. Methods: In total, 201 patients with HCV genotype 1b were examd. for L31F/M/V variants or a Y93H variant by the polymerase chain reaction invader assay. Results: L31M and Y93H variants were detected in 4.6 and 21.4 % of patients, resp. Patients with an L31M variant had no significant characteristics. Patients with a Y93H variant had significantly higher HCV RNA levels (6.5 ± 0.5 log copies per mL vs 6.1 ± 0.7 log copies per mL, $p = 0.0002$), higher frequency of mutant type of the IFN-sensitivity-detg. region (88.4 % vs 71.7 %, $p = 0.0251$), and higher frequency of TT genotype at rs8099917 of IL28B (91.7 % vs 54.3 %, $p < 0.0001$) than those with Y93 wild-type strains. Multivariate anal. identified HCV RNA levels [odds ratio (OR) 3.72, 95 % confidence interval (CI) 1.71-8.06, $p = 0.0009$] and TT genotype at rs8099917 (OR 7.45, 95 % CI 2.11-26.4, $p = 0.0018$) as factors assocd. with the presence of a Y93H variant. Conclusion: The presence of a Y93H variant was assocd. with higher HCV RNA levels and TT genotype at rs8099917 of IL28B. Thus, patients with a Y93H variant may be ideal candidates for IFN-based therapy rather than IFN-free therapy, although the high viral load of these patients may reduce the response rate of IFN-based therapy.

Indexing

Immunochemistry (Section15-2)

Section cross-reference(s): 3

Concepts

Animal gene

IL28B; clin. features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay

Biological study, unclassified; Properties; Biological study

Aging, animal
Blood platelet
Genetic polymorphism
Genotypes
Hepatitis C
Hepatitis C virus
Homo sapiens
Human
Immunotherapy
Leukocyte
Sex

Substances

57-88-5 Cholesterol, biological studies
60-27-5 Creatinine
635-65-4 Bilirubin, biological studies
9000-86-6 Alanine aminotransferase
9000-97-9 Aspartate aminotransferase
9001-26-7 Prothrombin
9004-61-9 Hyaluronic acid
9046-27-9 γ-GTP

clin. features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay

Biological study, unclassified; Biological study

目标物质未做重点研究

SciFinder® A CAS SOLUTION

文献检索练习

- 检索“多功能载药蛋白纳米粒”的文献。被引次数最高的文献来自哪份期刊？发文最多的研究机构是哪家？该研究领域专利多还是期刊多？在中国发文最多的机构是哪一家？其中研究紫杉醇（paclitaxel）的有多少文献？
- 检索中药五味子的相关文献。找出分析五味子素（ Schisandrin）的相关文献
- 检索你导师发表的文章，并判断他的主要研究方向。

SciFinder® A CAS SOLUTION

美国化学文摘社北京代表处

010-62508026

china@acs-i.org

SciFinder®
A CAS SOLUTION